<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458263</url>
  </required_header>
  <id_info>
    <org_study_id>rmc003515ctil</org_study_id>
    <nct_id>NCT00458263</nct_id>
  </id_info>
  <brief_title>Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature</brief_title>
  <acronym>ISS</acronym>
  <official_title>One Arm, Open Study to Assess Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One arm, open, prospective, intervention study to assess biochemical markers of growth&#xD;
      response to Growth Hormone treatment in 20 Children, aged 3-9 years old, with idiopathic&#xD;
      short stature. All participants will be treated with Growth Hormone during the first year of&#xD;
      the study (and then in accordance with the local ethic requirement, to supply drug which is&#xD;
      not approved for the indication used in the study, for additional 3 years) and then will be&#xD;
      followed up for the next 3 years. The impact of Growth Hormone therapy on clinical laboratory&#xD;
      parameters that are indicative of the growth response will be assessed by collecting blood&#xD;
      and urine samples during the 4 years study period. The primary endpoints are measurements of&#xD;
      height and growth velocity during the year of Growth Hormone treatment, the height at the&#xD;
      beginning of puberty and final height. Secondary endpoints are psychological parameters,&#xD;
      assessed by questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One arm, open prospective intervention study to assess biochemical markers of growth response&#xD;
      to Growth Hormone treatment in 20 children, aged 3-9 years old, with idiopathic short&#xD;
      stature.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. To determine axiological and biochemical markers for growth response&#xD;
&#xD;
        2. To assess the period of time necessary to determine the parameters which will&#xD;
           differentiate between responders and non-responders&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Ages 3 to &lt;9 years&#xD;
&#xD;
        2. Short stature with height &gt;2.25 Standard Deviation below the mean&#xD;
&#xD;
        3. Prepubertal (Tanner stage I) at commencement of trial&#xD;
&#xD;
        4. Peak Growth Hormone above 10ng/ml in at least one provocative test for Growth Hormone&#xD;
           secretion&#xD;
&#xD;
        5. Signing Informed consent forms&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Intra Uterine Growth Retardation&#xD;
&#xD;
        2. Growth retardation associated with malignancy, severe chronic disease, genetic syndromes&#xD;
           and endocrine disorders&#xD;
&#xD;
        3. Diabetes&#xD;
&#xD;
        4. Treatment with any medical product which may interfere with Growth Hormone effects&#xD;
&#xD;
      Methods:&#xD;
&#xD;
        1. All participants will be treated with Growth Hormone during the first year of the study&#xD;
           (and then in accordance with the local ethic requirement, to supply drug which is not&#xD;
           approved for the indication used in the study, for additional 3 years) and then will be&#xD;
           followed up for the next 3 years.&#xD;
&#xD;
        2. The impact of Growth Hormone therapy on clinical laboratory parameters that are&#xD;
           indicative of the growth response will be assessed by collecting blood and urine samples&#xD;
           during the 4 years study period.Samples will be test for biochemical markers of bone&#xD;
           formation and resorption&#xD;
&#xD;
        3. The primary endpoints are measurements of height and growth velocity during the year of&#xD;
           Growth Hormone treatment, the height at the beginning of puberty and final height.&#xD;
           Secondary endpoints are psychological parameters, assessed by questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>every 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth velocity</measure>
    <time_frame>every 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Height at beginning of puberty</measure>
    <time_frame>At the biginning of puberty</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Final height</measure>
    <time_frame>When acheiving final height</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychological parameters</measure>
    <time_frame>once a year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c and IGF-1</measure>
    <time_frame>at baseline. after 3 months and than every 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatotropin growth hormone recombinant human</intervention_name>
    <description>daily Sub Cutaneous injections</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 3 to &lt;9 years&#xD;
&#xD;
          -  Short stature with height &gt;2.25 Standard Deviation below the mean&#xD;
&#xD;
          -  Prepubertal (Tanner stage I) at commencement of trial&#xD;
&#xD;
          -  Peak Growth Hormone above 10ng/ml in at least one provocative test for Growth Hormone&#xD;
             secretion&#xD;
&#xD;
          -  Signing informed consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intra Uterine Growth Retardation&#xD;
&#xD;
          -  Growth retardation associated with malignancy, severe chronic disease, genetic&#xD;
             syndromes and endocrine disorders&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Treatment with any medical product which may interfere with Growth Hormone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider Children Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>schneider children medical center of Israel</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>April 8, 2007</study_first_submitted>
  <study_first_submitted_qc>April 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <last_update_submitted>January 1, 2013</last_update_submitted>
  <last_update_submitted_qc>January 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Hormone treatment</keyword>
  <keyword>ISS</keyword>
  <keyword>Biochemical markers</keyword>
  <keyword>Growth response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

